Key Takeaways
- Consolidation phase, not a growth breakout: Revenue grew ~10–11% against a 15% historical average while fixed assets doubled; management frames the next 18–24 months as gestation before FY28 acceleration.
- US label strategy validated: Nearly $10 million in own-label revenue since inception, achieved without price cuts, and the US business overall is growing 25–30%.
- Margins structurally improving: COGS fell from 43% to 39% of revenue over three years, opex from 27% to 24.5%, lifting EBITDA margin from 17% to 38.5%.
- Pipeline build-out is the real story: Ten products pending FDA review, 14 acquired ANDAs being readied, Phase 3 facility adding eight lines, and oncology injectables entering exhibit batches.
- What to watch next quarter: Whether the ten pending FDA approvals convert, the oncology facility starts commercials, and the INVIMA audit outcome in April.
US Business: The Label Bet Paying Off
- Own-label traction: The front-end, own-label route in the US has generated nearly $10 million since inception last year, achieved through supply chain efficiency and general shortages rather than price cuts.
- Product revenue mix steady: The 75:25 split between product revenue and milestone/profit-share revenues held consistent, with growth in both streams.
- Approval engine running: Methylprednisolone, a complex suspension injectable, approved in the first cycle; first-cycle approvals also secured for emulsion injections and emulsion ophthalmic products. Average approval timelines of 14–15 months beat the industry norm of ~20 months.
- Ten ANDAs in the queue: Ten products are pending FDA review and expected to clear within the next few months, which would take the approved portfolio to roughly 65 ANDAs under Caplin's name.
- Acquired ANDAs as a second engine: Fourteen ANDAs acquired from outside over recent months are being actively prepared for market entry sometime in the next year.
- US margins still a drag: Current US revenue (~₹323 cr for 9 months) comes from existing, somewhat commoditized products; all ANDA acquisitions and R&D are expensed rather than capitalized, depressing margins. As newer products launch and 13–15 lines become operational, expenses cap out and incremental revenue flows to the bottom line.
Vivek Partheeban: "This goes to show that, this was a decision, in hindsight, was a good one."
Pipeline & Facilities: Building for FY28
- Phase 3 facility fast-tracked: Two lines already completed at Caplin One Lab's Unit 2; three more expected by September–October this year; operations to start early next year with at least five of the eventual eight lines active.
- Oncology injectables entering execution: Exhibit batches begin this month; four acquired ANDAs are oncology injectable products with an organic pipeline of 12 more; first filings expected by end of this year, and some products could reach market late this year or early next year via the PAS route (3 months stability plus 6 months review).
- Oncology facility near commercial: Commercials expected to start within the next two months.
- Vizag API plant scaling: Three critical APIs already scaled up; targeting two to three more per month; first DMF filing from this site expected by end of this year.
- Blow-fill-seal investment: Order placed with Rommelag for a fully integrated machine; 14 products taken on for development in this space, with first approvals expected in late FY27 or FY28.
- Ophthalmic and pre-filled syringe pipeline: Twelve to thirteen products expected to complete development in the next 12 months, with approvals anticipated by end of next year, setting up 2028 for a wave of launches.
- Ophthalmic ointments entry: Adding sterile ophthalmic ointments will complete the full gamut of sterile product capabilities.
- Mexico facility: A ₹100–125 cr investment for ointments and liquid orals; no bio-equivalence studies required, enabling immediate market entry upon completion.
- Oncology market share trajectory: Single-digit share in the first couple of years, then inching toward double digits as the portfolio broadens.
C.C. Paarthipan: "If you look at actually injectable facilities whether it is in China or US, always big boys game. In two years, we will be in a position to complete 14 to 15 lines exporting products to US, which is of course, it's not that easy, and we'll be one among the maybe three or four from India."
Margins & Cost Structure
- Structural margin expansion: COGS as a percentage of revenue dropped from 43% to 39% over three years; opex fell from 27% in FY24 to 24.46% in the current year; EBITDA margin consequently rose from 17% to 38.5%.
- Operating cost stability despite expansion: New plants commercialized in the last 3–4 months and top-line growth have not pushed up operating costs, because infrastructure and manpower were pre-built and pre-operating expenses were capitalized. Freight cost as a percentage of turnover also declined after the shift from FOB to freight basis roughly 1.5 years ago.
- PAT margin comfort zone: Management is comfortable in the 26–29% PAT range and expects that to continue; once newer initiatives fire on all cylinders, margins could rise further.
- Receivables temporarily elevated: Receivables rose to 121 days from the 118-day benchmark because remittances in the last 10 days of December were delayed by Christmas holidays; January remittances more than compensated, and normalization back to 120 days is expected by March or June.
- Tax rate steady: Expected to remain around 20–21% in the coming years.
Latin America: The Next Growth Vector
- Chile shifting to private market: Chile is 75–80% tender-driven with high import duties and late government payments; the company is pivoting to the private market, where the first month of focused effort yielded ~$100,000.
- Chile ambition: Management sees Chile becoming a top-5 market in 2–3 years, with $10–$15 million per year definitely possible and perhaps beyond. Oral solid dosage products are being submitted for registration now, with results expected in 1–2 years.
- Mexico and Chile timeline: Meaningful revenue from these larger markets is 18–24 months away, consistent with the broader consolidation-phase narrative.
- Colombia audit readiness: Two former senior INVIMA inspectors have been recruited as executives to prepare all factories for audits; the oncology facility and CP 1 expect an INVIMA audit in April.
Operating Model & Competitive Positioning
- Video SOP system: A proprietary visual SOP platform converts standard operating procedures into step-by-step video scripts in regional languages for factory workers; video viewing is mandatory before operating machines, and remote monitoring tracks night-shift compliance. A patent has been filed, and AI governance architecture will be added in the future.
- Compliance record intact: EU GMP and Saudi FDA audits completed with no critical observations, extending a consistent compliance track record.
- Asset-light for specialties: The company is expanding its asset-light model, using CMOs/CDMOs, into Korea, Turkey, and Russia for specialty products, in addition to existing China sourcing.
- China: collaborate, don't compete: Management concedes it cannot compete with China in cephalosporins, penicillin, biosimilars, or GLP APIs (semaglutide API dropped from $500 to $80); the strategy is to continue sourcing from China in these areas and collaborate rather than fight.
- In-house mix rising: The in-house versus outsourcing mix will shift from 60:40 to 70:30, but China outsourcing for cephalosporin/penicillin will not be reduced.
- Post-capex strategy: Once the remaining capex is spent in the next 12–18 months, manufacturing capex will decline and the focus will shift to meaningful inorganic growth: acquiring products, distribution companies, or value-adding companies. A war chest is being built for outsized opportunities.
C.C. Paarthipan: "In pharma manufacturing, non-compliance is not a learning failure or a training failure, it's an execution visibility failure."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FDA approvals | Ten pending products to clear review | Next few months |
| Acquired ANDA commercialization | Fourteen acquired ANDAs brought to market | Sometime in the next year |
| Phase 3 facility operational | At least five of eight lines active | Early next year |
| Oncology injectable filings | First few products filed | End of this year |
| Oncology injectable market entry | Some products reach market via PAS route | Late this year or early next year |
| Oncology facility commercials | Facility starts generating revenue | Next two months |
| Vizag API DMF filing | First DMF filed from Vizag site | End of this year |
| Blow-fill-seal approvals | First products approved | Late FY27 / FY28 |
| Ophthalmic/PFS approvals | Twelve to thirteen products up for approval | End of next year |
| Receivables normalization | Back to 120-day benchmark | By March, or June if not |
| Capex completion | Remaining manufacturing capex spent | Next 12–18 months |
| Mexico facility | Investment of ₹100–125 cr; immediate market entry on completion | No date given |
| Chile top-5 market | $10–$15 million annual revenue | Next 2–3 years |
| PAT margin | 26–29% sustained | Ongoing |
| Tax rate | 20–21% | Coming years |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue growth | 10.6% YoY |
| Total income growth | 11.2% YoY |
| COGS growth | 9% YoY, despite increase in turnover |
| COGS as % of revenue | 39%, down from 43% three years ago |
| Opex growth | 6% YoY, below revenue growth |
| Opex as % of total revenue | 24.46%, vs 25.62% in corresponding period and 27% in FY24 |
| EBITDA margin | 38.5%, vs 36.5% in corresponding period |
| PBT | ₹589 cr, +17.8% YoY; 35.2% of revenue |
| PAT | ₹477 cr, +20.5% YoY; 28.5% of revenue vs 26.3% last year |
| Net worth | ₹3,338 cr as of December |
| Cash and cash equivalents | ₹1,381 cr, vs ₹1,180 cr after ₹180 cr capex |
| Cash flow from operations | ₹368 cr for nine months, vs ₹284 cr in corresponding period |
| Free cash flow | ₹188 cr for nine months, after ₹180 cr capex |
| Receivables days | 121 days, vs 118 days |
| Inventory | 67% of turnover including transit goods; 55% in warehouses, 12% in transit |
| US label revenue | Nearly $10 million since inception last year |
| CSL consolidated EBITDA (Q3) | ₹31.09 cr |
| US market revenue (9 months) | ₹323 cr |
| US market PBT margin (9 months) | 34% (per an analyst's math) |
| Product revenue vs milestone/profit share mix | 75:25 |
| ANDAs approved under Caplin's name | ~65 expected within a short period |
| ANDAs acquired from outside | ~14 over the last few months |
| Average ANDA approval timeline | 14–15 months, vs industry ~20 months |
| Capex already spent (of ₹1,000 cr plan) | ₹385 cr; ₹153 cr capitalized, ₹124 cr WIP, ₹88.54 cr advances |
| Remaining capex timeline | 12–18 months |
| Tax rate | 20%–21% |